Navigation Links
Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform

HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At the April AACR Annual Meeting, Indivumed presented data which provide a sound scientific basis for a new drug test-platform to predict drug response in patients.

Tumor tissue-derived primary cell lines are currently the first choice for cancer drug testing. During their clonal selection and expansion, however, their gene and protein expression patterns change significantly, thereby losing many of their primary characteristics. Primary cell cultures are useful tools because they better reflect the molecular reality in tumors. A previous Indivumed study, however, showed that within 10 passages and after 10-12 weeks in culture, the molecular characteristics and target expression of these cells change significantly in >20% of cancer relevant genes, e.g. EGFR, HER2, VEGF, p53, CEA.

Gene expression data from short-term cultivated colorectal cancer primary cells show that in contrast to long-term cultivation (>1 month) primary cells cultivated for up to 72h do not change the molecular expression level of most cancer relevant genes. Some of the genes that play a role in cell to cell contact and tissue organization changed expression levels at various time points when compared to instantly frozen tumor tissue. These data provide a sound basis for Indivumed's new drug test-platform which allows molecular and functional analysis of molecular anti-cancer agents in a clinically meaningful system and, thus, a better prediction of clinical drug response.

Indivumed is a privately held biotech company focused on the generation, characterization and interpretation of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Washington, D.C., Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of o
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/21/2014)... Aug. 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ... of regenerative medicine, announced today the appointments of Andrew ... newly expanded Board of Directors. With these additions, the ... of whom are independent. Andy Arno ... emerging growth companies. He is currently Managing Director of ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down methamphetamine offenders and make ... in Missouri blocked the ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... is natural that all customers using the services of online ... for them and getting their order within the shortest possible ... and well-taken. This site assures new and regular clients with ... security. It uses the most updated methods to make every ...
... HeartWare International, Inc. (Nasdaq: HTWR ) (ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the Canaccord ... 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time). ...
Cached Medicine Technology:A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to International Clients 2HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2
(Date:8/21/2014)... effective vaccination, polio is considered nearly eradicated. Each year ... scientists of the University of Bonn, together with colleagues ... that was able to resist the vaccine protection to ... outbreak in the Congo in 2010. The pathogen could ... results appear now in the magazine PNAS . ...
(Date:8/21/2014)... August 21, 2014 Glioblastoma Multiforme ... Therapeutic Approaches Target High Unmet Need in Newly ... of the Glioblastoma Multiforme (GBM) therapeutics market within ... and Japan. The report provides estimates of market ... 2020. It also covers disease epidemiology, treatment algorithms, ...
(Date:8/21/2014)... 2014 One of the emerging trends ... experience is an increasing adoption of non-invasive administration products. ... the patient through their convenient application, they find more ... a medical device used for the administration of drugs ... and paranasal sinus such as allergic and non-allergic rhinitis ...
(Date:8/21/2014)... Hospital officials, community leaders and elected officials ... new building at Mount Sinai Queens, marking the completion ... expansion and modernization project. During the event, hospital ... Kaufman, Chairman of the nearby Kaufman Astoria Studios, for ... will be named. The project, which began late ...
(Date:8/21/2014)... According to a new market research report "Near Field ... Auxiliary), Application (Payment, Transportation, Booking, Data Sharing, Service, Access ... - Global Forecasts to 2022", published by MarketsandMarkets, the ... by 2022 at an estimated CAGR of 8.83% from ... and 105 Figures spread through 298 Pages and in-depth ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 3Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 4Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 5Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 6Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 7Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 3Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 4Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 2Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 3Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 4
... , MONDAY, April 9 (HealthDay News) -- People ... problems, such as ulcers and bleeding, and also for ... The findings highlight the need to develop new ... arthritis patients, according to the Mayo Clinic researchers. ...
... than 60 percent of breast cancer survivors report at ... diagnosis, according to a new study led by a ... University of Pennsylvania. The findings are part of a ... late effects of breast cancer treatment and creating strategies ...
... , MONDAY, April 9 (HealthDay News) -- Hispanics and ... and Medicare and Medicaid patients are less likely to receive ... says. University of Michigan School of Public Health researchers ... were 1.5 times more likely to receive antidepressants than blacks ...
... , (WASHINGTON, April 9, 2012) A novel anti-leukemia compound with ... (T-ALL), suggesting its potential to become a new highly targeted ... according to results from a study published ... of the American Society of Hematology (ASH). ...
... 262 Pages | $29.95 | ISBN13: 9780199892594) "Roberta Ness teaches how ... as its subject, Dr. Ness shows how, with a little know-how and ... selves.", ... Medicine, National Academies of Science "Great science depends on innovative ...
... in-patient rehabilitation are more likely to land back in ... poorly, show signs of depression and lack social support ... Branch (UTMB) at Galveston. Hospital readmission for older adults ... billion annually. , Among the first of such ...
Cached Medicine News:Health News:Gastro Woes Often Strike Rheumatoid Arthritis Patients 2Health News:Breast cancer patients suffer treatment-related side effects long after completing care 2Health News:Breast cancer patients suffer treatment-related side effects long after completing care 3Health News:Minorities, Medicare Recipients Less Likely to Get Antidepressants 2Health News:Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment 2Health News:Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment 3Health News:Innovation Generation 2Health News:Innovation Generation 3Health News:Predictors identified for rehospitalization among post-acute stroke patients 2Health News:Predictors identified for rehospitalization among post-acute stroke patients 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: